MAPT haplotype diversity in multiple system atrophy

Catherine Labbé, Michael G. Heckman, Oswaldo Lorenzo-Betancor, Melissa E Murray, Kotaro Ogaki, Alexandra I. Soto-Ortolaza, Ronald L. Walton, Shinsuke Fujioka, Shunsuke Koga, Ryan J. Uitti, Jay A Van Gerpen, Ronald Carl Petersen, Neill R Graff Radford, Steven G Younkin, Bradley F Boeve, William P. Cheshire, Phillip Anson Low, Paola Sandroni, Elizabeth Coon, Wolfgang SingerZbigniew K Wszolek, Dennis W Dickson, Owen A Ross

Research output: Contribution to journalArticle

11 Scopus citations


Introduction: Multiple system atrophy (MSA) is a rare progressive neurodegenerative disorder. MSA was originally considered exclusively sporadic but reports of association with genes such as . SNCA, . COQ2 and . LRRK2 have demonstrated that there is a genetic contribution to the disease. . MAPT has been associated with several neurodegenerative diseases and we previously reported a protective association of the . MAPT H2 haplotype with MSA in 61 pathologically confirmed cases. Methods: In the present study, we assessed the full . MAPT haplotype diversity in MSA patients using six . MAPT tagging SNPs. We genotyped a total of 127 pathologically confirmed MSA cases, 86 patients with clinically diagnosed MSA and 1312 controls. Results: We identified four significant association signals in our pathologically confirmed cases, two from the protective haplotypes H2 (MSA:16.2%, Controls:22.7%, p = 0.024) and H1E (MSA:3.0%, Controls:9.0%, p = 0.014), and two from the rare risk haplotypes H1x (MSA:3.7%, Controls:1.3%, p = 0.030) and H1J (MSA:3.0%, Controls:0.9%, p = 0.021). We evaluated the association of MSA subtypes with the common protective H2 haplotype and found a significant difference with controls for MSA patients with some degree of MSA-C (MSA-C or MSA-mixed), for whom H2 occurred in only 8.6% of patients in our pathologically confirmed series (P < 0.0001). Conclusions: Our findings provide further evidence that . MAPT variation is associated with risk of MSA. Interestingly, our results suggest a greater effect size in the MSA-C compared to MSA-P for H2. Additional genetic studies in larger pathologically confirmed MSA series and meta-analytic studies will be needed to fully assess the role of . MAPT and other genes in MSA.

Original languageEnglish (US)
JournalParkinsonism and Related Disorders
StateAccepted/In press - Apr 14 2016


  • Association study
  • Genetics
  • MAPT
  • Multiple system atrophy

ASJC Scopus subject areas

  • Geriatrics and Gerontology
  • Clinical Neurology
  • Neurology

Fingerprint Dive into the research topics of 'MAPT haplotype diversity in multiple system atrophy'. Together they form a unique fingerprint.

  • Cite this

    Labbé, C., Heckman, M. G., Lorenzo-Betancor, O., Murray, M. E., Ogaki, K., Soto-Ortolaza, A. I., Walton, R. L., Fujioka, S., Koga, S., Uitti, R. J., Van Gerpen, J. A., Petersen, R. C., Graff Radford, N. R., Younkin, S. G., Boeve, B. F., Cheshire, W. P., Low, P. A., Sandroni, P., Coon, E., ... Ross, O. A. (Accepted/In press). MAPT haplotype diversity in multiple system atrophy. Parkinsonism and Related Disorders.